All In Biotech

Drug Trial Radar · NCT06977438

GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward

GLOW (GLP-1 Plus Lifestyle for Overall Wellness)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,020 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,020

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jan 31, 2031

Study completion Jan 31, 2032

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; Novo Nordisk A/S
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Conditions

  • Obesity, Childhood

Interventions

  • SemaglutideDrug

    All participants in this study will receive treatment with Semaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Body Mass Index (BMI) ReductionTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Minnesota, Center for Pediatric Obesity Medicine

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.